Gyre Therapeutics, Inc. Reports Q2 2026 Financial Results

What Happened
Gyre Therapeutics, Inc. (GYRE) announced its financial results for the three and six months ended June 30, 2026 via a press release dated August 7, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8‑K filed the same day. The Form 8‑K was signed by CEO and President Ying Luo.

Key Details

• Press release announcing quarterly and year‑to‑date financial results issued and furnished on August 7, 2026 (Exhibit 99.1).
• Results cover the three- and six-month periods ended June 30, 2026.
• Disclosure reported under Item 2.02 (Results of Operations and Financial Condition) of Form 8‑K.
• Form 8‑K was signed by Ying Luo, Chief Executive Officer and President, on August 7, 2026.

Why It Matters
This filing notifies investors that Gyre has released its latest quarterly and year-to-date financial performance; the press release will contain the specific metrics (revenue, earnings/losses, cash position, and any operational highlights) investors typically use to assess near-term company health. Retail investors should read the furnished press release (Exhibit 99.1) for the detailed numbers and any management commentary or updates that could affect the stock.